BioPIPS or the Biologics Pharma Innovation Programme Singapore aims to strengthen local biomanufacturing capabilities and transform Singapore’s biologics manufacturing facilities into agile factories of the future. It works through a consortium model consisting leading biopharma companies and Singapore’s public sector R&D agencies and universities. BioPIPS is modelled after PIPS.
Vision: Transform biologics manufacturing through the introduction of new technologies and products into Singapore’s manufacturing facilities.
Objectives:
- Leverage public sector R&D capabilities to address problem statements from local biologics manufacturing facilities to enhance manufacturing productivity and operational efficiency
- Transform the existing biologics manufacturing operations in Singapore so that the manufacturing sites are best-in-class within their respective manufacturing network and well positioned for the introduction of new products and novel manufacturing technologies
- Leverage strong foundation through synergies in operations, resources, learning and collaboration of technologies with PIPS